Mutant FLT3 signaling contributes to a block in myeloid differentiation

References

• Minden M. Growth factor requirements for normal and leukemic cells. Seminars in Hematology 1995; 32: 162–182
   PubMed Web of Science ®Google Scholar
• Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Critical Reviews in Oncology/Hematology 1993; 4: 595–613
   Google Scholar
• Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 1994; 145: 283–288
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918
   PubMed Web of Science ®Google Scholar
• Rosnet O, Marchetto S, DeLapeyriere O, Brinbaum D. Murine FLT3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991; 6: 1641–1650
   PubMed Web of Science ®Google Scholar
• Matthews W, Jordan C T, Wiegand G W, Pardoll D, Lemischka I R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143–1152
   PubMed Web of Science ®Google Scholar
• Small D, Levenstein M, Kim E, Burrow C, Amin S, Civin C. STK-1 is expressed in a subpopulation of human bone marrow enriched for CD34 + progenitor/stem cells and in a number of leukemic cell lines. Blood 1992; 80: 296a
   Google Scholar
• Rosnet O, Schiff C, Pebusque M J, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110–1119
   PubMed Web of Science ®Google Scholar
• Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk2/Flt-3, is selectively expressed in CD34 + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proceedings of the National Academy of Sciences (USA) 1994; 91: 459–463
   PubMed Web of Science ®Google Scholar
• Lyman S D. Biology of flt3 ligand and receptor. International Journal of Hematology 1995; 62: 63–73
   PubMed Web of Science ®Google Scholar
• McKenna H J. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Current Opinion in Hematology 2001; 8: 149–154
   PubMed Web of Science ®Google Scholar
• Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, Mannoni P, et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene 1993; 8: 909–918
   PubMed Web of Science ®Google Scholar
• deLapeyriere O, Naquet P, Planche J, Marchetto S, Rottapel R, Gambarelli D, et al. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation 1995; 58: 351–359
   PubMed Web of Science ®Google Scholar
• Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque M J, Marchetto S, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584–2593
   PubMed Web of Science ®Google Scholar
• Drexler H G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588–599
   PubMed Web of Science ®Google Scholar
• Carow C E, Levenstein M, Kaufmann S H, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089–1096
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin J D, Moore K A, Boast S, Goff S P, Lemischka I R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147–161
   PubMed Web of Science ®Google Scholar
• Lyman S D, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157–1167
   PubMed Web of Science ®Google Scholar
• Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan J F, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643–648
   PubMed Web of Science ®Google Scholar
• McClanahan T, Culpepper J, Campbell D, Wagner J, Franz-Bacon K, Mattson J, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 1996; 88: 3371–3382
   PubMed Web of Science ®Google Scholar
• Lyman S D, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S. Structural analysis of human and murine flt3 ligand genomic loci. Oncogene 1995; 11: 1165–1172
   PubMed Web of Science ®Google Scholar
• Lisovsky M, Braun S E, Ge Y, Takahira H, Lu L, Savchenko V G, Lyman S D, Broxmeyer H E. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996; 10: 1012–1018
   PubMed Web of Science ®Google Scholar
• McKenna H J, Stocking K L, Miller R E, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489–3497
   PubMed Web of Science ®Google Scholar
• Meierhoff G, Dehmel U, Gruss H J, Rosnet O, Birnbaum D, Quentmeier H, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 1995; 9: 1368–1372
   PubMed Web of Science ®Google Scholar
• Brasel K, Escobar S, Anderberg R, de Vries P, Gruss H J, Lyman S D. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995; 9: 1212–1218
   PubMed Web of Science ®Google Scholar
• Zheng R, Levis M, Piloto O, Brown P, Baldwin B R, Gorin N C, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 2004; 103: 267–274
   PubMed Web of Science ®Google Scholar
• Lyman S D, Jacobsen S E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101–1134
   PubMed Web of Science ®Google Scholar
• Dosil M, Wang S, Lemischka I R. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Molecular and Cellular Biology 1993; 13: 6572–6585
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring H J, deLapeyriere O, Beslu N, Lavagna C, Marchetto S, et al. Expression and signal transduction of the FLT3 tyrosine kinse receptor. Acta Haematologica 1996; 95: 218–223
   PubMed Web of Science ®Google Scholar
• Zhang S, Broxmeyer H E. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochemical and Biophysical Research Communications 2000; 277: 195–199
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. Journal of Experimental Medicine 2000; 192: 719–728
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. Journal of Biological Chemistry 1998; 273: 14962–14967
   PubMed Web of Science ®Google Scholar
• Tse K F, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766–1776
   PubMed Web of Science ®Google Scholar
• Zhang S MC, Broxmeyer H E. Flt3 signaling involves tyrosly-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. Journal of Leukocyte Biology 1999; 65: 372–380
   PubMed Web of Science ®Google Scholar
• Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg J P, et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 1999; 13: 1374–1382
   PubMed Web of Science ®Google Scholar
• Rottapel R, Turck C W, Casteran N, Liu X, Birnbaum D, Pawson T, Dubreuil P. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. Oncogene 1994; 9: 1755–1765
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434–2439
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–1337
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Kopecky K J, Meshinchi S, Appelbaum F R, Slovak M L, Willman C L, Radich J P. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589–3595
   PubMed Web of Science ®Google Scholar
• Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38–43
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Woods W G, Stirewalt D L, Sweetser D A, Buckley J D, Tjoa T K, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89–94
   PubMed Web of Science ®Google Scholar
• Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997; 11: 1442–1446
   PubMed Web of Science ®Google Scholar
• Xu F, Taki T, Yang H W, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. British Journal of Haematology 1999; 105: 155–162
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605–1609
   PubMed Web of Science ®Google Scholar
• Baldwin B RZR, Small D. FLT3 is not frequently mutated in solid tumors. Blood 2001; 98: 156b
   Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907–3914
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624–631
   PubMed Web of Science ®Google Scholar
• Chen P, Levis M, Brown P, Kim K T, Allebach J, Small D. FLT3/ITD mutation signaling includes suppression of SHP-1. Journal of Biological Chemistry 2005; 280: 5361–5369
   PubMed Web of Science ®Google Scholar
• Kim K T, Baird K, Ahn J Y, Meltzer P, Lilly M, Levis M, Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005; 105: 1759–1767
   PubMed Web of Science ®Google Scholar
• Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164–3173
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002; 21: 2555–2563
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Molecular Cell 2004; 13: 169–178
   PubMed Web of Science ®Google Scholar
• Levis M, Allebach J, Tse K F, Zheng R, Baldwin B R, Smith B D, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885–3891
   PubMed Web of Science ®Google Scholar
• Kelly L M, Liu Q, Kutok J L, Williams I R, Boulton C L, Gilliland D G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310–318
   PubMed Web of Science ®Google Scholar
• Kelly L M, Kutok J L, Williams I R, Boulton C L, Amaral S M, Curley D P, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proceeding of the National Academy of Sciences (USA) 2002; 99: 8283–8288
   PubMed Web of Science ®Google Scholar
• Abu-Duhier F M, Goodeve A C, Wilson G A, Care R S, Peake I R, Reilly J T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology 2001; 113: 983–988
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335
   PubMed Web of Science ®Google Scholar
• Armstrong S A, Kung A L, Mabon M E, Silverman L B, Stam R W, Den Boer M L, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173–183
   PubMed Web of Science ®Google Scholar
• Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103: 1085–1088
   PubMed Web of Science ®Google Scholar
• Smith M L, Arch R, Smith L L, Bainton N, Neat M, Taylor C, et al. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. British Journal of Haematology 2005; 128: 318–323
   PubMed Web of Science ®Google Scholar
• Jiang J, Paez J G, Lee J C, Bo R, Stone R M, DeAngelo D J, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004; 104: 1855–1858
   PubMed Web of Science ®Google Scholar
• Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005; 105: 4792–4799
   PubMed Web of Science ®Google Scholar
• Armstrong S A, Mabon M E, Silverman L B, Li A, Gribben J G, Fox E A, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103: 3544–3546
   PubMed Web of Science ®Google Scholar
• Valtieri M, Tweardy D J, Caracciolo D, Johnson K, Mavilio F, Altmann S, et al. Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. Journal of Immunology 1987; 138: 3829–3835
   PubMed Web of Science ®Google Scholar
• Zheng R, Friedman A D, Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood 2002; 100: 4154–4161
   PubMed Web of Science ®Google Scholar
• Baldwin B R, Tse K -F, Small D. Transgenic mice expressing a constitutively activated FLT3 receptor display a myeloproliferative disease phenotype. Blood 2001; 98: 801a
   Web of Science ®Google Scholar
• Fagioli M, Grignani F, Ferrucci P F, Alcalay M, Mencarelli A, Nicoletti I, et al. Effect of the acute promyelocytic leukemia PML/RAR alpha protein on differentiation and survival of myeloid precursors. Leukemia 1994; 8(Suppl 1)S7–S11
   Google Scholar
• He L Z, Tribioli C, Rivi R, Peruzzi D, Pelicci P G, Soares V, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proceedings of the National Academy of Sciences (USA) 1997; 94: 5302–5307
   PubMed Web of Science ®Google Scholar
• Zheng R, Friedman A D, Levis M, Li L, Weir E G, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 2004; 103: 1883–1890
   PubMed Web of Science ®Google Scholar
• Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 2005; 105: 2107–2114
   PubMed Web of Science ®Google Scholar
• Tse K, Novelli E, Civin C, Bohmer F, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001–1010
   PubMed Web of Science ®Google Scholar
• Tse K F, Allebach J, Levis M, Smith B D, Bohmer F D, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027–2036
   PubMed Web of Science ®Google Scholar
• Levis M, Tse K F, Smith B D, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885–887
   PubMed Web of Science ®Google Scholar
• Mendel D B, Laird A D, Xin X, Louie S G, Christensen J G, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003; 9: 327–337
   PubMed Web of Science ®Google Scholar
• O'Farrell A M, Abrams T J, Yuen H A, Ngai T J, Louie S G, Yee K W, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605
   PubMed Web of Science ®Google Scholar
• Kelly L M, Yu J C, Boulton C L, Apatira M, Li J, Sullivan C M, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421–432
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly L M, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433–443
   PubMed Web of Science ®Google Scholar
• Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel M T, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr, Frankel S R, Miller W H, Jr, Scheinberg D A, Itri L M, Hittelman W N, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Degos L. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group. Leukemia 1994; 8(Suppl 2)S42–S47
   Google Scholar
• Sanz M A, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324
   PubMed Web of Science ®Google Scholar
• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Shao W, Fanelli M, Ferrara F F, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute 1998; 90: 124–133
   PubMed Web of Science ®Google Scholar
• Wang Z G, Rivi R, Delva L, Konig A, Scheinberg D A, Gambacorti-Passerini C, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998; 92: 1497–1504
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith B D, Small D, Gabrilove J L, Warrell R P, Jr, Pandolfi P P. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004; 104: 1145–1150
   PubMed Web of Science ®Google Scholar